1. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Issue 12 (December 2022) Authors: Meric-Bernstam, Funda; Beeram, Muralidhar; Hamilton, Erika; Oh, Do-Youn; Hanna, Diana L; Kang, Yoon-Koo; Elimova, Elena; Chaves, Jorge; Goodwin, Rachel; Lee, Jeeyun; Nabell, Lisle; Rha, Sun Young; Mayordomo, Jose; El-Khoueiry, Anthony; Pant, Shubham; Raghav, Kanwal; Kim, Jin Won; Patnaik, Amita; ... Journal: Lancet oncology Issue: Volume 23:Issue 12(2022) Page Start: 1558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗